Clinical trials market to $176B; APAC DCT rise
The global clinical trials market is forecast to reach $176.32 billion by 2030 as AI-enabled design and decentralized research reshape how sponsors run studies. For Asia-Pacific operators, the wire forecast lands alongside concrete China and Korea registry entries that show DCT platforms moving from concept into protocol design. Here is what the allowlisted sources verify.
Contents12 sections
Key Takeaways
- GlobeNewswire (15 July 2026) cites a Research and Markets report forecasting clinical trials spend of $176.32 billion by 2030 at a 6.8% CAGR.
- Near-term path: $127.16 billion in 2025 to $135.51 billion in 2026 (6.6% CAGR).
- APAC is named the fastest-growing region through 2030; North America remained largest in 2025.
- Registry anchors for the APAC DCT angle include China’s NCT07595289 and Korea’s completed NCT06005805.
Global clinical trials market at a glance
| Field | Detail |
|---|---|
| 2025 market size | $127.16 billion (report figure via GlobeNewswire) |
| 2026 market size | $135.51 billion; 6.6% CAGR from 2025 |
| 2030 forecast | $176.32 billion; 6.8% CAGR in forecast window |
| Largest region 2025 | North America |
| Fastest-growing region | Asia-Pacific through 2030 (China, India, Japan, Korea, Australia named) |
| Growth drivers cited | AI trial design, precision medicine, DCT/virtual trials, RWE, faster approvals |
| APAC DCT examples | NCT07595289 (China); NCT06005805 (South Korea, completed) |
What numbers did the July 2026 market report put on clinical trials?
On 15 July 2026, GlobeNewswire carried a Research and Markets summary of the “Clinical Trials Market Report 2026.” The release states the global clinical trials market is forecast to expand from $127.16 billion in 2025 to $135.51 billion in 2026, a 6.6% compound annual growth rate, and to reach $176.32 billion by 2030 at a 6.8% CAGR during the forecast period.
Historical support listed in the wire includes rising pharmaceutical R&D investment, expanding pipelines, chronic disease prevalence, established regulatory frameworks, and greater CRO outsourcing. Those are market-model inputs, not audited national accounts.
Primary wire: GlobeNewswire — Global Clinical Trials Market to Reach $176.32 Billion by 2030 (15 July 2026).
Why do AI and decentralized trials dominate the growth narrative?
The same release says future growth will be driven by AI-enabled clinical trial design, precision medicine studies, decentralized and virtual trials, real-world evidence requirements, and pressure to accelerate drug approval timelines. Named trends include AI-powered patient recruitment and trial optimization, real-time remote patient monitoring, patient-centric designs, and increased outsourcing to CROs.
Technology examples in the wire are illustrative, not APAC-exclusive: IQVIA’s June 2024 launch of One Home for Sites is cited as a unified platform combining remote monitoring, telehealth, electronic consent, and digital data collection. Thermo Fisher’s October 2025 agreement to acquire Clario for up to $9.4 billion is cited as consolidation in endpoint data and trial operations.
For APAC readers, the useful takeaway is directional: vendors and CROs are packaging DCT and AI tools as the next efficiency layer, while regional growth is expected to outpace mature markets that already hold the largest spending base.
Where does Asia-Pacific sit in the regional forecast?
North America was the largest regional clinical trials market in 2025, according to the GlobeNewswire summary, supported by extensive pharmaceutical R&D, research infrastructure, and technology adoption. Asia-Pacific is expected to be the fastest-growing region through 2030 as investment, patient access, research capacity, and global trial activity increase across China, India, Japan, South Korea, and Australia.
That split — North America largest, APAC fastest — is the planning frame for site networks, CRO capacity bets, and hybrid protocol design. It does not by itself quantify APAC’s 2030 dollar share; the public wire excerpt does not publish a regional dollar table.
What China registry evidence shows DCT platform testing?
Beyond market models, ClinicalTrials.gov shows China-origin protocols that treat decentralization as a primary research question. DP-DCT 1.0 (NCT07595289), sponsored by The Third Xiangya Hospital of Central South University, is registered as not yet recruiting, with an estimated start of 1 August 2026.
The study aims to evaluate feasibility of decentralized trials with community resources, test a Digital Platform for Decentralized Clinical Trials (DP-DCT), and compare continuous glucose monitoring versus self-monitoring of blood glucose in adults with type 2 diabetes on dapagliflozin. Estimated enrollment is 120. Primary feasibility endpoints include completion of predefined DCT procedures such as remote consent, electronic data capture, device connectivity, direct-to-patient drug delivery, and scheduled follow-ups.
Registry record: ClinicalTrials.gov NCT07595289 — DP-DCT 1.0 decentralized platform study in China.
What has South Korea already tested on DCT feasibility?
South Korea offers a completed feasibility signal. NCT06005805, led by Seoul National University Hospital, evaluated whether decentralized elements are feasible in Korea, including local laboratory testing, wearable adherence assessment, self-kit specimens, investigational medication delivery and tracking, real-time remote interviews, and e-consent.
The interventional study enrolled 20 participants, started 21 August 2023, and completed 31 October 2023. It is small and not a pivotal drug efficacy trial, but it is a primary registry proof that Korean investigators have already operationalized DCT logistics end-to-end.
Registry record: ClinicalTrials.gov NCT06005805 — DCT feasibility study in South Korea.
How should APAC sponsors read the $176 billion figure?
Treat the $176.32 billion 2030 figure as a syndicated market forecast republished on an allowlisted wire, not as a regulator census. Use it to size vendor and CRO conversations. Pair it with registry and regulator evidence when making operational bets:
- If the thesis is “APAC grows fastest,” the GlobeNewswire regional statement supports that direction.
- If the thesis is “DCT is live in APAC,” China and Korea NCT records support active protocolization.
- If the thesis is “AI already cut cycle time by X% across APAC,” that specific efficiency claim is not in the wire excerpt reviewed here and should not be invented.
Related NovaPharma APAC coverage on discovery partnerships and regional trial context can help readers connect market sizing to company-level moves without leaving the silo.
What remains unproven
Keep these limits explicit:
- Research and Markets methodology, segment definitions, and APAC dollar shares are behind the commercial report paywall and are not independently audited here.
- IQVIA and Thermo Fisher/Clario examples are global vendor signals; they are not evidence that every APAC regulator has finalized identical DCT rules.
- NCT07595289 has not yet recruited; feasibility outcomes are prospective.
- NCT06005805 proves operational feasibility in a 20-person Korean setting, not commercial DCT scale across APAC oncology portfolios.
Verified core: the July 2026 GlobeNewswire forecast path to $176.32 billion by 2030, APAC as fastest-growing region in that summary, and two ClinicalTrials.gov DCT anchors in China and Korea.
Related NovaPharma coverage
- Insilico Medicine alliance with Bora Pharmaceuticals
- Nektar pipeline and clinical program context
- TGA Australia drug approval pharmaceutical coverage
Frequently Asked Questions
How large is the global clinical trials market forecast to 2030?
A 15 July 2026 GlobeNewswire release on Research and Markets’ Clinical Trials Market Report 2026 forecasts the market to grow from $127.16 billion in 2025 to $135.51 billion in 2026 (6.6% CAGR) and to reach $176.32 billion by 2030 at a 6.8% CAGR.
Is Asia-Pacific expected to grow fastest in clinical trials?
Yes, according to the same GlobeNewswire market summary. North America was the largest regional market in 2025, while Asia-Pacific is described as the fastest-growing region through 2030, citing expansion in China, India, Japan, South Korea, and Australia.
What APAC registry evidence shows decentralized trial activity?
ClinicalTrials.gov lists China-based DP-DCT 1.0 (NCT07595289), a not-yet-recruiting decentralized platform study in type 2 diabetes, and a completed Seoul National University Hospital DCT feasibility study in South Korea (NCT06005805).
Primary Sources
This article follows our editorial standards. Report a correction via editorial contact.
